Kornimate/medical-research-clean huggingface dataset:
glucose and blood pressure during pregnancy

Conditions: Gestational Diabetes; Pre-Eclampsia; Blood Pressure

Summary: the purpose of this research is to examine the beneficial effects of regular, non-invasive, glucose (sugar) assessment on glucose (sugar) and blood pressure regulation during pregnancy to help in predicting gestational diabetes and preeclampsia.

this is an open-label pilot trial for the labclasp combined with standard clinical care compared to standard clinical on \[glucose\] and blood pressure during pregnancy. potential study participants will be pre-screened using questionnaires and review of their clinical records. once the consent has been obtained, participants will undergo screening to confirm eligibility. subjects who meet all criteria will be randomized to either lc+sc or sc cohorts for 24-39wks depending upon their gestational duration at enrollment. study measures including anthropometrics, surveys/questionnaires, 24hr abpm, accelerometry, and an oral glucose tolerance test (ogtt). furthermore, the investigators will obtain repeated (annual) subject information including vitals, labs, medications, and development of cardiometabolic disorders for up to 10yrs in follow-up by reviewing mayo clinic medical records.

Eligibility criteria:
inclusion criteria: * age range: 18-45 years (inclusive) * body mass index (bmi) ≤40kg/m2 * \>1 risk factor for gdm * \<16wks gestation * gender: only females will be recruited into this study * ability to provide written informed consent exclusion criteria: * presence of chronic kidney disease (creatinine \>2.5mg/dl) and/or active cancer * smoking * multiple pregnancies * congenital abnormalities * use of chronic medications which influence blood \[glucose\] or \[insulin\] * subsequent diagnosis of gdm or preeclampsia
the effect of medication reminder technology on medication adherence and hypertension outcomes

Conditions: Medication Adherence; Blood Pressure

Summary: this study to evaluates how a med reminder affects the patient's ability to take medications as prescribed


Eligibility criteria:
inclusion criteria: * poor medication adherence * high blood pressure exclusion criteria: -
acute lower gastrointestinal bleeding (alibi study) in italy

Conditions: Lower GI Bleeding

Summary: unlike upper gi bleeding, for lgib there is still a paucity of data on clinical presentation, patient characteristics, pathways of care and outcomes for lgib patients. in-hospital mortality ranges from 1.2% to 8.8% (2-4), according to retrospective studies, but data from prospective series are still limited (5). present multicentre, prospective, observational study was designed to explore these areas, to assess variations in practice management and to identify factors associated with patient outcomes.


Eligibility criteria:
inclusion criteria: * adult patients with acute lower gi bleeding exclusion criteria: * age below 18 years * bleeding patients with an upper gi source
comparative study between the airgotm system and standard tests in the assessment of the respiratory function

Conditions: Respiration Disorders

Summary: the study aims at evaluating the airgotm system's performance, as compared to standard pulmonary function tests.

primary endpoint: • to test the airgotm system's respiratory rate recording accuracy at rest and during physical exercise, as compared to standard tests. secondary endpoints: * to test the accuracy of the airgotm system's derived respiratory parameters (tidal volume, minute ventilation, tiffeneau-pinelli index, fev1 and vo2max) at rest and during physical exercise, as compared to standard tests. * to test comfort and subjects' compliance with the airgotm system during long term recording (24 hours).

Eligibility criteria:
inclusion criteria: * non-smoker healthy volunteers, * able to perform a routine respiratory function test (spirometry and cardiopulmonary exercise testing), * aged between 18 and 75 years, * who signed a written informed consent. exclusion criteria: * present cardiac comorbidities (eg. coronary artery disease, heart failure, arrhythmias); * history of coronary artery disease or heart failure; * respiratory comorbidities (eg. asthma, chronic obstructive disease, sleep apnoea, lung interstitial disease); * pregnancy; * former smoker of \>5 p/y; * severe trauma or major surgery in the last year; * chest pain; * obesity (bmi \>30).
mechanisms underlying cardiovascular consequences associated with covid-19 and long covid

Conditions: COVID-19

Summary: aim 1. characterize cardiovascular phenotypes of long covid by cardiopulmonary, meta-bolic, and cardiac mechanical/physiological responses to exercise and microvascular vasomotor function. aim 2. identify intercellular signaling between immune cells and cardiac cells associated with microvascular phenotypes of long covid.

as many as 40-60% of patients who recovered from mild or moderate acute covid have reported what is now called long covid - multiple, persistent or recurrent symptoms lasting 6-9 months (or longer) following initial illness.1-4 fatigue, dyspnea, and chest pain are the most common symptoms. others include palpitations, lightheadedness, and syncope. all these cardiovascular symptoms can be debilitating, resulting in worse quality of life and morbidity.5, 6 treatment options are limited.

Eligibility criteria:
inclusion criteria: * age \> 18, \< 75 yrs * history of lab-confirmed covid * symptomatic at \>12 wks post-acute covid (cases) * recovered by 8wks post-acute covid (controls) exclusion criteria: * any history of critical illness * chronic kidney disease, stage \>4 * pre-covid: hfref, cabg, arrhythmia; pulmonary hypertension, pulmonary embolus, interstitial lung disease (ild), o2 dependence; dementia, stroke, autonomic dysfunction; coagulopathy * post-covid: ild, o2 dependence

Keywords: long covid-19
a study of lasmiditan on simulated driving performance in healthy participants

Conditions: Healthy

Summary: the purpose of this study is to evaluate the effect of lasmiditan on simulated driving performance in healthy participants. participants are expected to complete each of four study periods, which will last a total of about 10 days. during this time, participants will remain in the clinical research unit. screening must be completed within 28 days before the start of the study. follow-up will be completed about one week after discharge.


Eligibility criteria:
inclusion criteria: * are overtly healthy males or females, as determined through medical history and physical examination. * possess a valid driver's license and is an active driver at screening. driven a minimum of 8,000 miles (about 13,000 kilometers) per year for the preceding 3 years. * have a score of \<10 on the epworth sleepiness scale. exclusion criteria: * have a history within 3 months of admission, or current treatment for, a sleeping disorder (including excessive snoring, obstructive sleep apnea), or a chronic painful condition that interferes with the subject's sleep. * have a history of difficulty either falling asleep or staying asleep in the previous 3 months of admission that is considered clinically significant by the investigator. * are expected to use any other medication or dietary supplement to promote sleep including over the-counter sleep medications, during their participation in the study. * have traveled across 2 or more time zones (transmeridian travel) in the past 2 weeks prior to randomization. * have worked in a night shift in the past 2 weeks prior to randomization. * show a history of central nervous system (cns) conditions such as strokes, transient ischemic attacks, significant head trauma, seizures, cns infections, migraine, brain surgery, or any other neurological conditions that, in the opinion of the investigator, increase the risk of participating in the study. * show evidence of significant active neuropsychiatric disease (e.g., manic depressive illness, schizophrenia, depression) considered as clinically significant by the investigator.
warming iv fluids and incidence of hypotension

Conditions: Assault by Hot Fluids

Summary: this prospective, double-blinded, randomized, controlled study was undertaken to evaluate whether warming iv fluids (37 oc) resulted in lower incidence of hypotension, less ephedrine and transfusion requirement and lower fluid consumption than use of room-temperature fluids (22 oc) in cesarean delivery patients undergoing spinal anesthesia.

inadvertent perioperative hypothermia during cesarean delivery is not rare and frequently neglected, despite the recommendations by clinical guidelines. exposure to cold air and infusing non-warmed intravenous (iv) fluids are the other main sources of inadvertent hypothermia. spinal anesthesia used during the cesarean delivery has also been demonstrated to impair normal autonomic thermoregulatory control and extend inadvertent perioperative hypothermia. various measures such as pre-warming of patients or fluids before anesthesia, peroperative warming of iv fluids and active/passive cutaneous warming techniques have all been used to prevent or to reduce inadvertent perioperative hypothermia. this prospective, double-blinded, randomized, controlled study was undertaken to evaluate whether warming iv fluids (37 oc) resulted in lower incidence of hypotension, less ephedrine and transfusion requirement and lower fluid consumption than use of room-temperature fluids (22 oc) in cesarean delivery patients undergoing spinal anesthesia. the hypothesis was that in elective caesarean delivery patients undergoing spinal anesthesia, warming intravenous fluids, would reduce the incidence of hypotension, ephedrine and transfusion requirement and volume consumption. thus, the primary outcome measure of the present study was the incidence of intraoperative maternal hypotension and ephedrine requirement during spinal anaesthesia for caesarean section. secondary outcome measures were total volume consumption, blood loss, pain scores, shivering and maternal and foetal side effects.

Eligibility criteria:
inclusion criteria: * inclusion criteria were previous cesarean delivery and breech presentation. exclusion criteria: * exclusion criteria included parturients younger than 18 and older than 43 years, significant coexisting disease such as preeclampsia or eclampsia, thyroid disorders, neurological disorders, increased risk of intra-operative hemorrhage (such as placenta accreta), and any contraindication to regional anaesthesia such as bleeding disorders or local infection.
basic sensations coming from the bladder

Conditions: Healthy; Overactive Bladder Syndrome

Summary: a major complication in studies to identify the nature of bladder sensations is language. it is difficult, if not near impossible, for the lay person, with no knowledge of physiology, anatomy or pathology, to put into simple terms a description of basic visceral sensations. therefore, before the investigators can speculate about the detailed mechanisms generating sensation the investigators must overcome this language and communication difficulty. this will be addressed in the present study. there are important reasons why the investigators must identify the mechanisms generating the different sensations as the bladder fills. one of them is that these are basic physiological mechanisms which need to be better understood.


Eligibility criteria:
inclusion criteria: healthy volunteers * healthy students from the university of maastricht well versed in dutch. patients * patients with oab diagnosed by their urologist using the criteria of more than 8 micturitions on three consecutive days. before the start of any anticholinergic or other therapy. patients on anticholinergic therapy will be asked to stop this therapy for at least 10 days before they enter the first session. * well versed in dutch. exclusion criteria: healthy volunteers * use of any medication (except oral contraceptives) * surgical history of the abdomen * urinary complaints (e.g. frequency, urgency) * urinary tract infection patients: * congestive heart disease or history of heart failure * presence of urinary tract infection. these patients will be treated by antibiotics.

Keywords: focus groups overactive bladder bladder sensations
training with mobile application in breast cancer

Conditions: Breast Cancer

Summary: endocrine hormonal therapy (eht) applied to avoid recurrence and metastasis of the breast cancer has also side effects which do not threaten life; however, it does negatively effects quality of life. the objective of this study was to determine the effects on quality of life of a mobile app-based (e-mobile) education for supportive care of patients with breast cancer receiving adjuvant endocrine hormonal therapy. the data were collected to with face to face and/or telephone interviews at 2 time points: prior to the initiation (t0) and after the completion (t1) of mobile app-based education. patients were received education via mobile app for 12 weeks during which they were contacted in every 15 days; a mobile app-based (e-mobile) education was provided, including information about breast cancer definition, treatment process, symptoms management, adequate nutrition, regular physical activity and coping with stress. in this process, the control group patients were provided with standard care.

mobile devices have an increasing role for the patient care and its use in the field of oncology creates promising opportunities for supportive cancer care and patient education. mobile applications were established for the supportive cancer care but their area of use is limited. although there are many field specific medical mobile applications, there are few training programs for the benefit of patients. however, these are innovative tools and provide accessibility, individual training and consultancy in order for the patients to be able to cope with side effects of the treatment; thus, improving their quality of life, symptom management and distress.

Eligibility criteria:
inclusion criteria: * diagnosed with primary breast cancer, * non-metastatic, * hormone receptor positive (er positive and/or pr positive) * for whom adjuvant eht was implemented at least for three months exclusion criteria: * diagnosed with secondary breast cancer, * metastatic, * hormone receptor negative (er negative and/or pr negative)

Keywords: breast cancer quality of life endocrine hormonal therapy mobile phone mobil app education of patients smartphone
seri surgical scaffold support of the lower pole of the breast

Conditions: Recurrent Ptosis of the Breast

Summary: will the use of an fda approved highly purified silk scaffold; seri surgical scaffold help shape and hold the breast up on the chest preventing re-stretching and bottoming out of the breast in breast reduction or augmentation-mastopexy patients? the amount of stretch will be measured manually as well as percent of breast tissue measured with the canfield vectra 3-d imaging system reporting the amount of breast tissue above and below the nipple level.

patients having augmentation mastopexy or breast reduction will be informed about seri scaffold and allowed to have seri support included in their surgery or not. if the choose the scaffold will be placed under the skin in the lower pole of the breast as an internal hammock to help take weight off of the breast and potentially help prevent future stretch of the lower pole.

Eligibility criteria:
inclusion criteria: age =\>18 years * requesting procedure * no active cancer or infection exclusion criteria: * known allergy to silk * pregnant or lactating

Keywords: recurrent ptosis reduction mammoplasty mastopexy
study of the chinese prescription weiqi decoction on chronic atrophic gastritis

Conditions: Gastritis

Summary: the purpose of this study is to evaluate the efficacy and safety of the chinese prescription weiqi decoction on chronic atrophic gastritis.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic atrophic gastritis * male of female patients between 18-65 years old * written informed consent exclusion criteria: * combine with malignant pathology on epithelial dysplasia of gastric mucosa * combine with duodenal ulcer or gastric ulcer * combined with severe heart, gallbladder, kidney, endocrine system, hemopoietic system or nervous system disease. * pregnancy or breast feeding women, or unwilling to have contraception.

Keywords: chronic atrophic gastritis traditional chinese medicine
memory aid for informed consent in alzheimer's research

Conditions: Alzheimer's Disease; Aging

Summary: the purpose of this trial is to test whether a memory and organizational aid in the form of a document that summarizes and simplifies a study's key points can improve the decision-making abilities and competency of mild to early moderate alzheimer's disease (ad) patients.

studies of mild to moderate alzheimer's disease (ad) patients reveal substantial variation in their ability to participate in an informed consent process. no published data show techniques that help an ad patient to participate in an informed consent. this research will address this issue by performing a randomized trial to test whether a memory and organizational aid can improve the decision-making abilities and competency of ad patients. this study will recruit 80 patients with mild to early moderate ad, and 30 non-demented elderly persons. the informed consent protocol for a hypothetical early-phase drug trial will be administered by a trained interviewer in the patient's home. the ad patients will be randomized to receive either the standard informed consent process or the intervention of the standard informed consent process plus the memory and organizational aid. all non-demented elderly individuals will receive the standard informed consent process. the interviewer will administer the protocol to participants and ask questions that will assess participant capacity to understand, appreciate, reason, and make a choice concerning enrollment in the hypothetical study.

Eligibility criteria:
inclusion criteria: * live within one hour drive of the university of pennsylvania's memory disorders clinic * education equivalent to 6th grade level * corrected visual acuity of at least 20/70 * speak english * diagnosed with possible or probable ad, or non-demented * mmse (mini mental state exam) \>= 18

Keywords: informed consent memory aid
a phase 4 cross-sectional study of bone mineral density in hiv-1 infected subjects

Conditions: HIV Infections

Summary: a phase 4 study is to characterize the profile of low bone mineral density (bmd) in ≥ 50 year old male subjects and post-menopausal female subjects on any tenofovir disoproxil fumarate (tdf)-based regimen


Eligibility criteria:
inclusion criteria: * must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures. * hiv-1 infected subjects regardless of race or ethnicity * use of one of the following taken as a stable, continuous, nrti-containing antiretroviral (arv) regimen for ≥ 3 years are allowed (within-class change of agents other than tdf within 3 years of study entry are permitted as specified): * tdf plus pi/r-containing regimen including subjects who switched from one tdf plus pi/r regimen to another tdf plus pi/r regimen * a tdf plus non-pi/r-containing regimen including subjects who switched from one tdf plus non-pi/r regimen to another tdf plus non-pi/r regimen * a non-tdf nrti plus a pi/r-containing regimen including subjects who switched from one non-tdf nrti plus pi/r regimen to another non-tdf nrti regimen plus pi/r regimen * a non-tdf nrti plus a non-pi/r-containing regimen including subjects who switched from one non-tdf nrti plus non-pi/r regimen to another non-tdf nrti regimen plus non-pi/r regimen * of note, subjects in the non-tdf groups must have never taken a regimen that includes tdf (including previous exposure to tdf for pre-exposure prophylaxis (prep)) * subjects included in the tdf groups must have always taken a regimen that includes tdf. non-pi/r agents include non-nucleoside reverse transcriptase inhibitors (nnrtis), integrase inhibitors, triple nucleoside inhibitors and non-boosted protease inhibitors * male subjects must be ≥ 50 years of age * female subjects must be postmenopausal. menopause can be assumed to have occurred in a woman when there is either appropriate medical documentation of prior complete bilateral oophorectomy or permanent cessation of previously occurring menses \> 12 months as a result of ovarian failure or bilateral oophorectomy with documentation of hormonal deficiency by a certified healthcare provided * adequate records available to evaluate medical history for the 3 years prior to study entry exclusion criteria: * subject has a contraindication to dual-energy x-ray absorptiometry (dexa) scans * subject has a history of osteoporosis before initiating highly active antiretroviral treatment (haart)

Keywords: treatment experienced male greater than or equal to 50 years female postmenopausal
focused palliative care intervention in advanced heart failure

Conditions: Heart Failure; Quality of Life

Summary: this small pilot study will be assessing the the impact of a standardized, social-worker led, longitudinal palliative care intervention on alignment of patient and physician understanding of prognosis and goals of care. secondary objectives include assessing the impact of this intervention on documentation of advanced care planning and end of life preferences, symptom burden, quality of life and health care utilization.

patients will be assigned to one of two groups a) longitudinal goals of care discussion led by a palliative care-trained social worker or b) usual care + written information regarding advanced directives. the intervention group will be enrolled in the hospital and then be followed longitudinally for 3 months by a palliative care-trained social worker who will shepherd a conversation around prognosis, expectations, and goals of care. the results of these conversations will be documented in the electronic medical record and shared with the clinical team. clinical symptoms that are identified during these conversations will be evaluated by a palliative care physician who will relay suggestions regarding management to the primary treating clinician. baseline surveys will assess prognostic awareness, symptom burden, anxiety, depression, and quality of life for both groups. at the conclusion of the study, an individualized follow-up plan will be devised for each patient based on a needs assessment by the study social worker. patients assigned to the control/usual care arm will complete the same series of questionnaires as those assigned to the intervention group and will undergo usual in hospital and post-discharge treatment as directed by their care team. all control subjects will receive written advanced care planning and heart failure education materials as provided routinely to inpatients at brigham and women's hospital. at the 6 month visit following hospitalization, these patients will be asked to complete follow up questionnaires and then will be given the option to participate in the above verbal intervention and guided "goals and values" conversation that was provided to the intervention group.

Eligibility criteria:
inclusion criteria * symptomatic heart failure (nyha ii-iv) * hospitalized or recently for acute decompensation with at least one of the following high-risk features * prior hospitalization for heart failure (hf) within 1 year * age \> 80 years * chronic kidney disease (estimated glomerular filtration rate (egfr) \< 45 ml/min/m2) * systolic blood pressure \< 100 mm hg * serum sodium \< 130 meq/l * cardiogenic shock (cardiac index \< 2.0) * serious non-cardiovascular illness (e.g. advanced stage cancer, chronic obstructive pulmonary disease (copd) , or the like. * ability to provide informed consent * permission of attending physician exclusion criteria * anticipated major cardiac surgery, including ventricular assist device (vad) or transplant, within 3 months of enrollment * already enrolled in hospice or receiving outpatient palliative care

Keywords: heart failure palliative care